Jiuzhou Pharmaceutical(SH:603456) Zheng Quan Shi Bao Wang·2025-11-12 00:37Core Viewpoint - The article discusses the retirement of Huaxuan De, the former richest person in Taizhou, who plans to transfer his shares in Zhongbei Group and Taizhou GeDe to his daughters, marking a significant change in the ownership structure of Jiuzhou Pharmaceutical. Group 1: Share Transfer Details - Huaxuan De intends to transfer 42.50% of his shares in Zhongbei Group and 10% in Taizhou GeDe to his daughters, Huali Rong and Huaxiao Hui [1][2] - The share transfer includes 28.50% to Huali Rong and 14% to Huaxiao Hui, with the payment amounts being 41.33 million yuan and 20.48 million yuan respectively [1] - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's stock price, is approximately 2.476 billion yuan [1] Group 2: Company Background and Leadership Changes - Jiuzhou Pharmaceutical was founded in 1998, evolving from a struggling company to a prominent player in the pharmaceutical industry under Huaxuan De's leadership [3] - Huali Rong currently serves as the chairman of Jiuzhou Pharmaceutical, while Huaxiao Hui has resigned from her director position as of December 2024 [3][4] - Huaxuan De has been instrumental in the company's growth, transitioning it from raw material production to contract research and manufacturing [3] Group 3: Market Context and Implications - The transfer of shares signifies Huaxuan De's complete withdrawal from active management, potentially reducing distractions from the company's operations [7] - The recent legal issues surrounding Xu Xiren, a figure connected to Huaxuan De, have brought renewed attention to his legacy and the companies involved [5][6]